Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode how Medicare reimbursements shape Encompass Health’s margins? Each 10-K easily tops 250 pages, packed with therapy-minute tables and payor-mix footnotes. Sifting for occupancy trends or new-hospital pipeline data is time-consuming—and Form 4 insider activity can shift before you even finish reading.
Stock Titan’s AI solves that problem. Our platform delivers Encompass Health SEC filings explained simply: instant summaries that translate complex accounting into plain English, plus red-flag alerts for every Encompass Health 8-K material events explained. Whether you need the latest Encompass Health quarterly earnings report 10-Q filing or a deep dive into the Encompass Health annual report 10-K simplified, we surface the numbers that drive rehab capacity and Medicare revenue.
- Real-time feed: Get Encompass Health Form 4 insider transactions real-time and see which executives are buying or selling.
- AI-powered highlights: Instantly spot CMS rule changes, segment EBITDA, and debt covenants without combing through exhibits.
- Comprehensive coverage: From Encompass Health proxy statement executive compensation to shelf registrations, every filing type is here the moment EDGAR posts it.
Use cases professionals rely on:
- Monitor Encompass Health executive stock transactions Form 4 ahead of dividend announcements.
- Compare rehab unit margins quarter-over-quarter with our Encompass Health earnings report filing analysis.
- Stay ahead of acquisition news with automated alerts on fresh 8-Ks.
Stop skimming PDFs and start understanding Encompass Health SEC documents with AI. All filings, all insights—delivered when they matter.
Encompass Health Corporation is reaffirming its full-year 2025 outlook as it meets with investors and analysts in early December. The company continues to project net operating revenue between
For profitability, Encompass Health maintains guidance for 2025 Adjusted EBITDA in a range of
Encompass Health (EHC) reported solid Q3 2025 results. Net operating revenues rose to $1,477.5 million from $1,351.0 million, and net income attributable to Encompass Health increased to $126.5 million from $108.2 million. Diluted EPS was $1.24 versus $1.06. Adjusted EBITDA reached $300.1 million, up from $269.3 million.
For the nine months, revenues were $4,390.6 million (vs. $3,968.2 million) with net income attributable to Encompass Health of $420.1 million (vs. $334.8 million). Year‑to‑date cash from operations was $829.6 million. The company redeemed the remaining $100 million of 5.75% Senior Notes due 2025 and ended the quarter with long‑term debt (net of current) of $2,393.9 million.
Operations expanded with new hospitals and bed additions across multiple states. Management expects the FY26 IRF rule to lift Medicare payment rates by approximately 2.9% effective October 1, 2025. The One Big Beautiful Bill Act is estimated to produce about $180 million of additional current deductions and approximately $50 million in 2025 cash tax savings. Shares outstanding were 100,615,977 as of October 21, 2025.
Encompass Health (EHC) furnished its third‑quarter 2025 results via a press release and supplemental materials attached as Exhibits 99.1 and 99.2 to an Item 2.02/7.01 Form 8‑K. The materials include definitions and reconciliations for non‑GAAP measures such as adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
The company will discuss these results on an earnings call at 10:00 a.m. Eastern Time on Thursday, October 30, 2025. The furnished information is not deemed filed under the Exchange Act. The filing also details how the leverage ratio is calculated under the credit agreement and outlines the role of Adjusted EBITDA in covenant compliance and liquidity assessment, along with cautionary forward‑looking statements.
Encompass Health (EHC) director Greg D. Carmichael reported an automatic award of 23 restricted stock units (RSUs) on 10/15/2025. The filing shows these were credited at a $0 price as dividend-equivalent RSUs tied to the company’s common stock dividend program for non-employee directors.
According to the footnote, the RSUs credited equal the product of RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the stock’s $123.65 closing price on the payment date. Following the transaction, the form lists 18,631 securities beneficially owned in direct form.
Encompass Health (EHC) reported a director’s Form 4 activity on 10/15/2025. The director received 7 RSUs credited in connection with a common stock dividend and acquired 223 shares through the Directors Deferred Stock Investment Plan.
The RSUs were credited based on the company’s $0.19 per share dividend and a closing price of $123.65. The 223 shares were purchased at a weighted average price of $123.21. Following these transactions, the director beneficially owns 6,904 shares directly.
Encompass Health (EHC) reported an insider equity award tied to its dividend policy. A company director acquired 73 restricted stock units at a stated price of $0 on October 15, 2025, reflecting dividend-equivalent RSUs credited under existing award agreements. Following the transaction, the director beneficially owned 47,752 shares/units directly.
The RSU credit was calculated using a $0.19 per-share dividend and the $123.65 closing price on the payment date, per the explanation of responses.
Encompass Health (EHC) reported an insider equity change: director Leslye G. Katz acquired 73 restricted stock units on 10/15/2025 at $0 per unit. The award reflects dividend-equivalent RSUs tied to a $0.19 common stock dividend, calculated using the $123.65 closing price on the payment date. Following the transaction, Katz beneficially owned 47,752 Encompass Health common shares.
Encompass Health (EHC) director Kevin J. O’Connor reported an automatic credit of 14 restricted stock units (RSUs) on 10/15/2025. The award reflects dividend equivalents under outstanding RSU agreements tied to the company’s common stock dividend.
Per the footnote, the number of RSUs credited equals the product of the RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the $123.65 closing price on the dividend payment date. The transaction was recorded at $0. Following this entry, securities beneficially owned were listed as 9,895, held directly.
Encompass Health (EHC) director Form 4: On 10/15/2025, a non-employee director reported two acquisitions. First, 16 restricted stock units were credited at $0 pursuant to dividend-equivalent terms tied to outstanding RSUs. Second, 288 common shares were purchased at a weighted average price of $123.23 in multiple trades ranging from $123.19 to $123.24.
The RSU credit relates to a $0.19 per-share common dividend paid on October 15, 2025, using the closing price of $123.65 to calculate units. The share purchase reflects the Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to buy shares in the market. Following these transactions, direct beneficial ownership reported in Table I was 15,085 shares.
Encompass Health (EHC) director Nancy M. Schlichting reported an automatic credit of 33 restricted stock units (RSUs) on 10/15/2025. The award stems from dividend equivalents pursuant to outstanding RSU award agreements, reflecting Encompass Health’s common stock dividend of $0.19 per share and a closing price of $123.65 on the payment date. The transaction is recorded at $0 as it was an accrual, not a market purchase.
Following this transaction, Schlichting beneficially owns 21,219 shares, held directly.
FAQ
What is the current stock price of Encompass Health (EHC)?
What is the market cap of Encompass Health (EHC)?
